Liposomal amphotericin B (AmBisome®)

DRUG4 trials

Sponsors

Gilead Sciences, Poitiers University Hospital, Hospital Universitário Professor Edgard Santos

Conditions

Allergic Bronchopulmonary AspergillosisCutaneous Leishmaniasis, AmericanFebrile NeutropeniaFungal Infection

Phase 1

Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly

CompletedNCT06449040

Hospital Universitário Professor Edgard SantosCutaneous Leishmaniasis, American

Start: 2019-03-01End: 2023-09-01Updated: 2024-06-07

Phase 2

Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).

CompletedNCT02273661

Poitiers University HospitalAllergic Bronchopulmonary Aspergillosis

Start: 2014-11-19End: 2019-06-28Updated: 2020-06-09

Phase 4

ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia

TerminatedNCT00386997

Gilead SciencesFungal Infection

Start: 2006-11-30End: 2007-09-30Target: 20Updated: 2007-08-21

Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to Antibiotics

TerminatedNCT00421187

Gilead SciencesFebrile Neutropenia

Start: 2007-03-31End: 2008-05-31Updated: 2011-03-11

Related Papers

CT Imaging Assessment of Response to Treatment in Allergic Bronchopulmonary Aspergillosis in Adults With Bronchial Asthma.

2024-02-202 citations